Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.

Samankaltaisia teoksia

• Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.
  Tekijä: Smith, C, et al.
  Julkaistu: (2005)
• Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
  Tekijä: Hanke, T, et al.
  Julkaistu: (1998)
• Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara.
  Tekijä: Sharpe, S, et al.
  Julkaistu: (2003)
• Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions.
  Tekijä: Salio, M, et al.
  Julkaistu: (2003)
• Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma.
  Tekijä: Dunbar, P, et al.
  Julkaistu: (1999)